Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Cumberland Pharmaceuticals (CPIX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn | 2.47% |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn | 39.28% |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn | 12.12% |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn | -28.09% |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn | -36.57% |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 42.23% |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn | 8.71% |
| 10 | Cumberland Pharmaceuticals | 96.11 Mn | 92.24 Mn | - | -90.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -90.91% |
| Mar 31, 2026 | -172.48% |
| Dec 31, 2025 | 16.82% |
| Sep 30, 2025 | -66.37% |
| Jun 30, 2025 | 18.63% |
| Mar 31, 2025 | 42.44% |
| Dec 31, 2024 | 21.19% |
| Sep 30, 2024 | -12.25% |
| Jun 30, 2024 | -42.62% |
| Mar 31, 2024 | -147.45% |
| Dec 31, 2023 | -90.23% |
| Sep 30, 2023 | -28.79% |
| Jun 30, 2023 | 42.88% |
| Mar 31, 2023 | 29.30% |
| Dec 31, 2022 | -36.26% |
| Sep 30, 2022 | 40.08% |
| Jun 30, 2022 | -34.03% |
| Mar 31, 2022 | -226.16% |
| Dec 31, 2021 | 13.59% |
| Sep 30, 2021 | 13.24% |